Navigation Links
S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Date:2/21/2012

JERSEY CITY, N.J., Feb. 21, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys).  Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD). 

Lorexys' clinical development plan is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA).  Lorexys is a novel use fixed-dose combination (FDC) in an oral enteric formulation acting on the central nervous system (CNS) with therapeutic characteristics that benefit sufferers of sexual health disorders.  It is intended as a treatment for HSDD both as a standalone and as an adjunct to testosterone therapy for the disorder.

"The IND filing for Lorexys is an important milestone for our Company," stated Nicolas G. Sitchon, Chief Executive Officer. "The Lorexys Clinical Development Program represents S1's entry into the significant Women's Sexual Health Disorders field with a lead drug candidate having several potential advantages over other treatment options in development."

On the condition of FDA endorsement of an approvable Investigational New Drug application for Lorexys, the Company will conduct Multiple Ascending Dose (MAD) safety, tolerability, and exploratory efficacy Phase I-b studies on Lorexys in 2012.  Upon successful completion, the results from these studies will satisfy FDA requirements to commence Phase II studies for HSDD patients.

About S1 Pharmaceuticals, Inc.

S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health.  The most common type of Female Sexual Dysfunction (FSD) is a distressing loss of libido (lack of sexual interest) known as Hypoactive Sexual Desire Disorder (HSDD).  S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.

Contact:
press@s1pharma.com
(201) 839-0941


'/>"/>
SOURCE S1 Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals
3. Endo Pharmaceuticals to Present at J.P. Morgan Annual Global High Yield & Leveraged Finance Conference
4. Access Pharmaceuticals MuGard Added to Nationally Ranked Childrens Hospital of Colorado Pharmacy Formulary
5. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
6. Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
7. Jazz Pharmaceuticals to Announce 2011 Full Year and Fourth Quarter Financial Results on February 27, 2012
8. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
9. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
10. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
11. Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 , ... new health technologies, announced today " 10 Year Global ... health tech over the past ten years.   ... a decade, Health 2.0 has served as the preeminent ... connected with thousands of technologies, companies, innovators, and patient-activists ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting that ... alcohol abstinence for all women who are at risk ... U.S. each year and raises the risks of unprotected ... --> According to the Guttmacher Institute, there ... women of child-bearing age, who have sex without the ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 2016 , ... Hidden Cypress in Sun City is the place to be on March 3rd ... Frederick Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. ... special pricing on offers. In addition, prizes will be given away and light refreshments will ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... Tennessee (PRWEB) , ... February 13, 2016 , ... ... the Infusion Nurses Society (INS) states that vein visualization technology should be used ... by healthcare facilities around the world, the INS Standards mandate the use of ...
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
Breaking Medicine News(10 mins):